Cellular imaging predictions of clinical drug-induced liver injury.
暂无分享,去创建一个
Peter V. Henstock | Peter V Henstock | Jeffrey R. Chabot | J. Xu | D. de Graaf | Jinghai J Xu | Margaret C Dunn | Arthur R Smith | Jeffrey R Chabot | David de Graaf | M. Dunn | A.R. Smith
[1] Yuichi Sugiyama,et al. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? , 2002, AAPS PharmSci.
[2] S. Strom,et al. Influence of Matrigel-overlay on constitutive and inducible expression of nine genes encoding drug-metabolizing enzymes in primary human hepatocytes , 2005, Xenobiotica; the fate of foreign compounds in biological systems.
[3] D. Pessayre,et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. , 1998, Gastroenterology.
[4] P. Routledge,et al. Adverse drug reactions in elderly patients. , 2003, British journal of clinical pharmacology.
[5] R. Shah,et al. Can pharmacogenetics help rescue drugs withdrawn from the market? , 2006, Pharmacogenomics.
[6] K. Guggenheim. Paracelsus and the science of nutrition in the renaissance. On occasion of the 500th anniversary of his birth. , 1993, The Journal of nutrition.
[7] J. Xu,et al. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[8] C. Laggner,et al. Why drugs fail--a study on side effects in new chemical entities. , 2005, Current pharmaceutical design.
[9] D. B. Ross. The FDA and the case of Ketek. , 2007, The New England journal of medicine.
[10] William M. Lee,et al. Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions , 2005, Toxicologic pathology.
[11] Michael P Holt,et al. Mechanisms of drug-induced liver injury , 2006, The AAPS Journal.
[12] J. Senior. Drug hepatotoxicity from a regulatory perspective. , 2007, Clinics in liver disease.
[13] R. Sokol,et al. "Let there be bile"--understanding hepatic injury in cholestasis. , 2006, Journal of pediatric gastroenterology and nutrition.
[14] C. Casellas,et al. Effects of human pharmaceuticals on cytotoxicity, EROD activity and ROS production in fish hepatocytes. , 2004, Toxicology.
[15] A. Kalgutkar,et al. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[16] H. Zimmerman,et al. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver , 1978 .
[17] E. VargasCastrillón. Drug-induced liver toxicity. , 2001 .
[18] Jordi Muntané,et al. Mecanismos de lesión hepatocelular , 2007 .
[19] R. Ulrich,et al. Idiosyncratic toxicity: a convergence of risk factors. , 2007, Annual review of medicine.
[20] G. Aithal,et al. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. , 2007, Clinics in liver disease.
[21] K. Brouwer,et al. P-glycoprotein Expression, Localization, and Function in Sandwich-Cultured Primary Rat and Human Hepatocytes: Relevance to the Hepatobiliary Disposition of a Model Opioid Peptide , 2004, Pharmaceutical Research.
[22] P. Bernardi,et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.
[23] Lucila Ohno-Machado,et al. The use of receiver operating characteristic curves in biomedical informatics , 2005, J. Biomed. Informatics.
[24] Paul B Watkins,et al. Idiosyncratic Liver Injury: Challenges and Approaches , 2005, Toxicologic pathology.
[25] Raffaella Corvi,et al. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop. , 2007, Mutation research.
[26] A. Hołownia,et al. Tamoxifen cytotoxicity in hepatoblastoma cells stably transfected with human CYP3A4. , 2004, Biochemical pharmacology.
[27] K Walton,et al. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. , 2005, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[28] J. Uetrecht. Idiosyncratic drug reactions: past, present, and future. , 2008, Chemical research in toxicology.
[29] Jinsheng Xu,et al. Characterisation of some cytotoxic endpoints using rat liver and HepG2 spheroids as in vitro models and their application in hepatotoxicity studies. II. Spheroid cell spreading inhibition as a new cytotoxic marker. , 2003, Toxicology and applied pharmacology.
[30] G. Hamilton,et al. Isolation and culture of primary human hepatocytes. , 2005, Methods in molecular biology.
[31] M. Rissel,et al. Hepatotoxicity of tacrine: occurrence of membrane fluidity alterations without involvement of lipid peroxidation. , 2000, Journal of Pharmacology and Experimental Therapeutics.
[32] P Smith,et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.
[33] J H Lewis,et al. Drug-induced liver disease. , 2000, Clinics in liver disease.
[34] Stephen B Choi. Nefazodone (Serzone) withdrawn because of hepatotoxicity. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[35] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[36] M. Lucena,et al. Hepatotoxicity associated with the new antidepressants. , 2002, The Journal of clinical psychiatry.
[37] A. Kalgutkar,et al. NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine. , 2007, Chemical research in toxicology.
[38] J. Ou,et al. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. , 2006, American journal of physiology. Gastrointestinal and liver physiology.
[39] A. Scheen,et al. Thiazolidinediones and liver toxicity. , 2001, Diabetes & metabolism.
[40] K. Jeyaseelan,et al. Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity? , 2007, Toxicology and Applied Pharmacology.
[41] D. Pessayre,et al. Hepatotoxicity due to mitochondrial dysfunction , 2004, Cell Biology and Toxicology.
[42] R. Temple,et al. Hy's law: predicting serious hepatotoxicity , 2006, Pharmacoepidemiology and drug safety.
[43] M. Black,et al. Drug induced liver disease. , 1983, Postgraduate medical journal.
[44] M. Madariaga,et al. Drug-related hepatotoxicity. , 2006, The New England journal of medicine.
[45] R. Krauss,et al. When good drugs go bad , 2007, Nature.
[46] Diana Kazolias,et al. Use of Cryopreserved Human Hepatocytes in Sandwich Culture to Measure Hepatobiliary Transport , 2006, Drug Metabolism and Disposition.
[47] T. Baillie,et al. Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. , 2002, Chemical research in toxicology.
[48] Shigeo Abe DrEng. Pattern Classification , 2001, Springer London.
[49] David G. Stork,et al. Pattern Classification , 1973 .
[50] G. Kass,et al. Role of mitochondria in drug-induced cholestatic injury. , 2008, Clinics in liver disease.
[51] Y. N. Singh,et al. Potential for interaction of kava and St. John's wort with drugs. , 2005, Journal of ethnopharmacology.
[52] Hayley S. Brown,et al. Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies , 2007, Drug metabolism reviews.
[53] Dolores Diaz,et al. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. , 2004, Chemico-biological interactions.
[54] S. Strom,et al. Gene expression profiling of extracellular matrix as an effector of human hepatocyte phenotype in primary cell culture. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[55] U. Boelsterli,et al. Mitochondrial abnormalities--a link to idiosyncratic drug hepatotoxicity? , 2007, Toxicology and applied pharmacology.
[56] M. Hammami,et al. Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. , 2007, Life sciences.
[57] N. Nalini,et al. Antioxidant effect of 2‐hydroxy‐4‐methoxy benzoic acid on ethanol‐induced hepatotoxicity in rats , 2007, The Journal of pharmacy and pharmacology.
[58] R. Andrade,et al. Drug-induced hepatotoxicity , 2003, The New England journal of medicine.
[59] Neil Kaplowitz,et al. Idiosyncratic drug hepatotoxicity , 2005, Nature Reviews Drug Discovery.
[60] Albert P. Li,et al. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. , 2002, Chemico-biological interactions.
[61] F. Lombardo,et al. BIOACTIVATION OF THE NONTRICYCLIC ANTIDEPRESSANT NEFAZODONE TO A REACTIVE QUINONE-IMINE SPECIES IN HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROME P450 3A4 , 2005, Drug Metabolism and Disposition.
[62] L. Friedman,et al. Hepatotoxicity of antibiotics and antifungals. , 2003, Clinics in liver disease.
[63] B. H. Ch. Stricker,et al. Drug-induced Hepatic Injury , 1985 .